Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.47 |
| ▸ | CDK1 | P06493 | 12/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299100 | 0.93 | CDK1 (0.47) | CDK2CDK1IGF1RPTK2IKBKB | |
| SCHEMBL3301332 | 0.92 | CDK2 (0.48) | CDK2CDK1IGF1RPTK2IKBKB | |
| SCHEMBL3301841 | 0.89 | CDK2 (0.47) | CDK2CDK1IGF1RPTK2IKBKB | |
| SCHEMBL3301045 | 0.87 | CDK2 (0.46) | CDK2CDK1IGF1RPTK2IKBKB | |
| SCHEMBL3299553 | 0.87 | CDK2 (0.45) | CDK2CDK1IGF1RPTK2IKBKB | |
| SCHEMBL3299991 | 0.87 | MAPK8 (0.43) | CDK2CDK1IGF1RPTK2IKBKB | |
| SCHEMBL3301383 | 0.87 | CDK2 (0.42) | CDK2CDK1IGF1RPTK2IKBKB | |
| SCHEMBL3302490 | 0.86 | CDK2 (0.53) | CDK2CDK1IGF1RPTK2IKBKB | |
| SCHEMBL3301949 | 0.86 | CDK2 (0.44) | CDK2CDK1IGF1RPTK2IKBKB | |
| SCHEMBL3298130 | 0.84 | CDK2 (0.43) | CDK2CDK1PTK2IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093668-A1 | N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS | CHUK, IKBKB, IKBKE | CDK2 8/4885CDK1 15/4885IGF1R 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.